4.5 Article

A candidate dual vaccine against influenza and noroviruses

期刊

VACCINE
卷 29, 期 44, 页码 7670-7677

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.07.139

关键词

Norovirus; Influenza; P particle; M2e; Dual vaccine; Platform

资金

  1. National Institute of Health
  2. National Institute of Allergy and Infectious Diseases [R01 AI37093, R01 AI055649, R01 AI089634]
  3. Department of Defense [PR033018]
  4. NIH/NCRR [1UL1RR026314-01]
  5. Nipert Foundation

向作者/读者索取更多资源

The extracellular domain of the matrix protein 2 (M2e) of influenza viruses is highly conserved among all influenza A subtypes, making it a suitable target for a universal influenza vaccine. In this study, we demonstrated an enhanced immune response and protection of a chimeric M2e vaccine against influenza A viruses using our newly developed vaccine platform, the norovirus P particle, to present the M2e peptide. The 23-amino acid peptide was inserted into one of the surface loops of the P protein, resulting in 24 copies of M2e presented on each P particle. Significantly (P <0.001) increased antibody responses to M2e were observed in mice immunized with the P particle-M2e chimera compared with those immunized with the free M2e peptides. Mice immunized with the P particle-M2e vaccine were fully protected (100% survived) against lethal challenge of a mouse adapted human influenza virus PR8 (H1N1), while only low survival rates (<12.5%) were found in mice immunized with the free M2e peptides or wild type P particle. In addition, the mouse sera collected after immunization with the P particle-M2e vaccine were able to block the binding of norovirus virus-like particle and P particle to histo-blood group antigen receptors. These results suggest that the P particle-M2e chimera can be used as dual vaccine against both noroviruses and influenza viruses. (C) 2011 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据